Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AACR 2024 : Cancer vaccines get reintroduction with pathway

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 13, 2024 11:29am

73 Views

Post# 36036900

RE:RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway

May 13, 2024 - " Seeking ever more efficacious treatments, companies are now eyeing cancer vaccines, which experts say could be more powerful than other immunotherapies and may even provide a preventative measure against certain malignancies."

Scot Ebbinghaus, vice president of clinical research at explained that both cancer vaccines and immunotherapies, such as Merck’s blockbuster Keytruda (pembrolizumab), act on the T cells, which fight cancer. “The way PD-1 inhibitors work is they take the brakes off of those cells. The vaccines work by presenting tumor-specific antigens to the immune system, which activates even more anti-tumor T cells, potentially allowing pembrolizumab to have a stronger effect,”

BioNTech announced in October that the first patient in a Phase II trial of autogene cevumeran, an mRNA vaccine against pancreatic ductal adrenal cancer (PDAC), had been treated. The vaccine, which consists of an mRNA encoding for up to 20 neoantigens tailor-made for different patients, is delivered alongside the immune checkpoint inhibitor atezolizumab. The open-label, randomized trial has two arms. In the first, patients are treated with a combination of the vaccine, atezolizumab and standard chemotherapy. These patients will be compared to a second arm of patients who receive only standard chemotherapy.

https://classic.clinicaltrials.gov/ct2/show/NCT05968326?term=GO44479&draw=2&rank=1

The vaccine, jointly developed by BioNTech and Genentech, was previously tested against a host of solid tumors in a Phase 1 trial where it triggered a large cohort of neoantigen-specific T cells in PDAC patients, many of whom went for long periods without cancer recurrence. This is particularly important for PDAC, which has a high relapse rate and is notoriously difficult to treat. The Phase II trial will recruit 206 patients and is expected to be completed in 2029.

https://clinicaltrials.gov/study/NCT03289962?term=autogene%20cevumeran&rank=1

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024